Peter Houston: Could Pharma Use Tumblr and Survive?
In this 3-minute audio snippet, Peter Houston, founder of Flipping Pages Media Ltd, discusses the pros and cons of Tumblr and whether it is possible for pharma marketers to get involved with Tumblr. Is it too Early?
Tom Stossel: Debunking the “Conflict-of-Interest Narrative”
In this 5-minute audio snippet, Thomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, talks about what he calls the 'Conflict-of-Interest Narrative' or Myth, which is the subject of his new book, PharmaPhobia.
Pharmaguy™
Pharmaguy™ is a Pharma Marketing 'Constructive' Critic, Blogger & Chief Pundit at Pharmaguy.com
Ambre Morley: Vetting Celebrity Spokespersons to Ensure Return on Investment
In this 2-minute audio snippet, Ambre Morley, Associate Director, Product Communications, Novo Nordisk, talks about vetting Paula Deen as a paid celebrity spokesperson for the Novo Victoza diabetes drug franchise and the importance of measuring celebrity return on investment (ROI).
Shona Davies and Sean Nicholson: How Do You Define “Engagement?”
In this 3-minute audio snippet, Shona L. Davies, Communications & Programme Leader, Univadis, and Sean Nicholson, Senoir Director, Social Media, Intouch Solutions, define what they mean by social media
Jessica Federer: Empower Pharma Employees to Advance Digitalization in Your Organization
In this 1-minute audio snippet, Jessica Federer, Head of Digital Development at Bayer, talks about how Bayer employees its employees to advance the digitalization of the organization.
Peter Kirk: Sermo vs. Doximity = “Facebook” vs. “LinkedIn” for Docs
In this 3-minute audio snippet, Peter Kirk, CEO, Sermo, talks about the differences between Doximity and Sermo with regard to online physician discussions and the benefits of anonymity.
Roland Andersson & Thomas Krohn: Transcelerate BioPharma Initiative
In this 4-minute audio snippet, Roland Andersson, Director for Accenture's Life Sciences R&D practice, and Thomas Krohn, Director, Clinical Open Innovation, Eli Lilly, discuss the Transcelerate Biopharma initiative, the goals of which are to increase compliance and the productivity of clinical trials.
Pharmaguy™
Pharmaguy™ is a Pharma Marketing 'Constructive' Critic, Blogger & Chief Pundit at Pharmaguy.com
Andrew Schorr: To Engage Patients Pharma Must Commit to the Long Haul
In this 3-minute audio snippet, Andrew Schorr, Founder and Host of PatientPower.info, notes that pharma agency accounts come and go, but patients are living with their conditions day in and day out. Pharma has to be careful, says Schorr, when approaching patients about how they view the commitment.
